Values First Advisors Inc. Invests $75,000 in Relay Therapeutics, Inc. (NASDAQ:RLAY)

Values First Advisors Inc. purchased a new position in Relay Therapeutics, Inc. (NASDAQ:RLAY) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 10,579 shares of the company’s stock, valued at approximately $75,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. American International Group Inc. raised its holdings in shares of Relay Therapeutics by 4.0% in the 1st quarter. American International Group Inc. now owns 46,686 shares of the company’s stock worth $387,000 after buying an additional 1,810 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its stake in shares of Relay Therapeutics by 6.6% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 41,203 shares of the company’s stock valued at $292,000 after purchasing an additional 2,547 shares in the last quarter. Los Angeles Capital Management LLC grew its holdings in shares of Relay Therapeutics by 25.7% in the 1st quarter. Los Angeles Capital Management LLC now owns 13,939 shares of the company’s stock worth $116,000 after purchasing an additional 2,850 shares during the last quarter. ProShare Advisors LLC increased its position in shares of Relay Therapeutics by 14.9% during the 1st quarter. ProShare Advisors LLC now owns 26,214 shares of the company’s stock worth $218,000 after purchasing an additional 3,394 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in Relay Therapeutics by 7.2% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 54,917 shares of the company’s stock valued at $456,000 after purchasing an additional 3,684 shares during the last quarter. Institutional investors own 96.98% of the company’s stock.

Insider Activity at Relay Therapeutics

In other news, insider Peter Rahmer sold 13,708 shares of the business’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $8.19, for a total transaction of $112,268.52. Following the completion of the transaction, the insider now directly owns 391,929 shares in the company, valued at approximately $3,209,898.51. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Relay Therapeutics news, CFO Thomas Catinazzo sold 10,780 shares of the stock in a transaction on Monday, July 29th. The shares were sold at an average price of $8.56, for a total value of $92,276.80. Following the sale, the chief financial officer now directly owns 319,650 shares in the company, valued at approximately $2,736,204. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Peter Rahmer sold 13,708 shares of the business’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $8.19, for a total transaction of $112,268.52. Following the completion of the transaction, the insider now directly owns 391,929 shares of the company’s stock, valued at $3,209,898.51. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 38,011 shares of company stock worth $320,032. 4.32% of the stock is owned by insiders.

Relay Therapeutics Price Performance

Shares of NASDAQ:RLAY opened at $6.02 on Friday. The stock has a market cap of $799.11 million, a price-to-earnings ratio of -2.28 and a beta of 1.64. The company has a 50 day moving average of $7.01 and a 200-day moving average of $7.05. Relay Therapeutics, Inc. has a one year low of $5.70 and a one year high of $12.14.

Relay Therapeutics (NASDAQ:RLAY) last released its earnings results on Tuesday, August 6th. The company reported ($0.69) EPS for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.04. During the same quarter last year, the business posted ($0.81) EPS. Equities research analysts anticipate that Relay Therapeutics, Inc. will post -2.84 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. JPMorgan Chase & Co. dropped their price objective on shares of Relay Therapeutics from $23.00 to $21.00 and set an “overweight” rating for the company in a report on Tuesday, September 10th. Bank of America lifted their price objective on Relay Therapeutics from $20.00 to $24.00 and gave the company a “buy” rating in a research report on Tuesday, September 10th. Stifel Nicolaus restated a “buy” rating and issued a $28.00 target price on shares of Relay Therapeutics in a research note on Monday, September 16th. JMP Securities reaffirmed a “market outperform” rating and issued a $21.00 price target on shares of Relay Therapeutics in a report on Tuesday, September 17th. Finally, HC Wainwright restated a “buy” rating and issued a $19.00 price objective on shares of Relay Therapeutics in a research report on Monday, October 14th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $21.11.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.